Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
CERRITOS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ:STLN) ("STLN" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended September 30, 2026 and updated it's full-year 2026 guidance. Recent Operational Highlights Specialty Pharmacy Revenue was $109 million, up 44 percent year over year, and gross margin was 24 percent. Continued increase in the capture rate of fills written by Starling physicians was the primary contributor to year-over-year revenue growth in the specialty pharmacy.Capitated revenue grew 40 percent year over year in the third quarter, and our m